Clinical Trial Update: Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AVE5026 for the prevention of venous thromboembolism in acutely ill medical patients with restricted mobility has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• AVE5026

Snippet

Sponsor: Sanofi | Conditions: Venous Thromboembolism | Phase 3 | Status: TERMINATED